Chemomab Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Net Income	-19.34	-24.22	-27.65	-12.48	-5.95	-27.12	Upgrade
Depreciation & Amortization	-	0.07	0.06	0.03	0.02	0.28	Upgrade
Share-Based Compensation	-	1.49	3.21	2.02	0.13	1.16	Upgrade
Other Operating Activities	19.34	-0.95	4.01	-1.95	0.56	9.23	Upgrade
Operating Cash Flow	-	-23.61	-20.37	-12.37	-5.24	-16.46	Upgrade
Capital Expenditures	-	-0	-0.07	0.76	-0.04	-0.1	Upgrade
Change in Investments	-	15.88	19.6	-45.95	-0.02	0	Upgrade
Investing Cash Flow	-	15.88	19.53	-45.19	-0.06	-0.1	Upgrade
Share Issuance / Repurchase	-	3.5	-0.95	58.64	3.5	30.5	Upgrade
Other Financing Activities	-	-	0.14	2.44	1.25	-3.88	Upgrade
Financing Cash Flow	-	3.5	-0.81	61.07	4.75	26.62	Upgrade
Net Cash Flow	-	-4.23	-1.65	3.51	-0.55	10.07	Upgrade
Free Cash Flow	-	-23.61	-20.44	-11.61	-5.28	-16.55	Upgrade
Free Cash Flow Per Share	-	-2.01	-1.80	-1.12	-0.77	-38.44	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).